$RGEN News
Last published 1w ago
- 1w agoRGENRepligen Corporation to Present at Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President
- 1w agoRGENRepligen Announces $1 Billion Private Convertible Senior Notes TransactionGlobeNewswireWALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) ("Repligen"), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain
- 2w agoRGENRepligen Q3-26 Earnings Call - REPLIGEN CORPEarnings Call TranscriptsGood morning, and welcome to Repligen's third quarter of 2026 Earnings Conference Call. My name is Jillian, and I will be your operator. Following management's prepared remarks, we will open the call for questions. If yo
- 2w agoRGENREPLIGEN CORP - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoRGENRepligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceGlobeNewswireThird quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organicClosed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market
- 4w agoRGENRepligen to Report Third Quarter 2026 Financial ResultsGlobeNewswireWALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The Company
- 1mo agoRGENBLFSRepligen Completes Acquisition of BioLife SolutionsGlobeNewswireWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN, "Repligen", or the "Company")), a life sciences company focused on bioprocessing technology leadership, today
- 2mo agoRGENWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - REPLIGEN CORPEarnings Call TranscriptsHi, everyone. Welcome to day two of the Wells Fargo Healthcare Conference afternoon. We are excited to have Repligen here. We have CEO Olivier Loyo and CFO Jason Garland. Very excited to both of you here um and so you kn
- 3mo agoRGENRepligen Q2-26 Earnings Call - REPLIGEN CORPEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Repligen Q2 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you'd like to ask a question, please press star
- 3mo agoRGENRepligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceGlobeNewswireSecond quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organicGAAP operating income increased 1% year-over-year while adjusted operating income increased 55%Raising both FY26
- 3mo agoRGENRepligen to Acquire BioLife Solutions Conference Call - REPLIGEN CORPEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to the Repligen Corporation Acquisition of Biolife Solutions conference call. My name is Elizabeth, and I will be your coordinator. Please note that there will be a question an
- 3mo agoRGENBLFSRepligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation MediaGlobeNewswireFast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to
- 3mo agoRGENRepligen to Report Second Quarter 2026 Financial ResultsGlobeNewswireWALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The Company will
- 5mo agoRGENWILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE - REPLIGEN CORPEarnings Call TranscriptsAll right, good morning, everyone. Thanks for joining us for the Repligen management presentation. My name is Matt LaRue. I cover Repligen here at Blair. Very pleased to be joined this morning by Olivier Loiot, who is th
- 5mo agoRGENRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceGlobeNewswireWALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair
- 5mo agoRGENRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportGlobeNewswireWALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate
- 6mo agoRGEN2026 Global Healthcare Conference - REPLIGEN CORPEarnings Call TranscriptsAll right. We'll kick off our next session. Thanks, everyone, for joining us. My name is Mike Riskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and we're excited to host Repligen for our next Fi
- 6mo agoRGENRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of
- 6mo agoRGENRepligen Q1-26 Earnings Call - REPLIGEN CORPEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to Repligen Corporation's first quarter 2026 earnings conference call. My name is Samantha and I will be your coordinator. Please note there will be a question and answer sessi
- 6mo agoRGENRepligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceGlobeNewswireFirst quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 organic revenue
- 6mo agoRGENRepligen to Report First Quarter 2026 Financial ResultsGlobeNewswireWALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will
- 6mo agoRGENRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support NetworkGlobeNewswireWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen
- 8mo agoRGENRepligen Corporation to Present at Upcoming March ConferencesGlobeNewswireWALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three
- 8mo agoRGENRepligen Q4-25 Earnings Call - REPLIGEN CORPEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. My name is Jericho and I'll be your conference operator today. At this time, I would like to welcome everyone to the RepliGen 4th Quarter 2025 Earnings Call. All lines hav
- 8mo agoRGENRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial GuidanceGlobeNewswireFourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16%
- 9mo agoRGENRepligen to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company
- 10mo agoRGENRepligen Corporation to Present at J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan
- 11mo agoRGENRepligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsGlobeNewswireWALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance
- 11mo agoRGENRepligen Corporation to Present at Evercore Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th
- 1y agoRGENRepligen Corporation to Present at Upcoming November ConferencesGlobeNewswireWALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming
- 1y agoRGENRepligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial GuidanceGlobeNewswireRevenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing
- 1y agoRGENRepligen to Report Third Quarter 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will
- 1y agoRGENRepligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoRGENRepligen Corporation - Appeal, ReversedUS Patent Trial and Appeal Board
- 1y agoRGENRepligen Corporation to Present at Upcoming September ConferencesGlobeNewswireWALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming
- 1y agoRGENRepligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing DigitalizationGlobeNewswireWALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a
- 1y agoRGENRepligen Corporation (RGEN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoRGENRepligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial GuidanceGlobeNewswireRevenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735
- 1y agoRGENRepligen to Report Second Quarter 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will
- 1y agoAAPLMASSRGENTMO908 Devices Appoints Christopher D. Brown to its Board of DirectorsBusiness Wire908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation
- 1y agoRGENRepligen Announces Publication of the Company's 2024 Corporate Sustainability ReportGlobeNewswireWALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate
- 1y agoRGENRepligen Corporation to Present at William Blair Growth ConferenceGlobeNewswireWALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William
- 1y agoRGENRepligen Corporation to Present at Upcoming May Investor ConferencesGlobeNewswireWALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the
- 1y agoRGENRepligen Reports First Quarter 2025 Financial ResultsGlobeNewswireRevenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year
- 1y agoRGENRepligen to Report First Quarter 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will
- 1y agoRGENRepligen Appoints Jacob Johnson As Vice President Investor RelationsGlobeNewswireWALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the
- 1y agoMASSRGENRepligen Purchases Bioprocessing Analytics Portfolio from 908 DevicesGlobeNewswireWALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in
- 1y agoMASSRGENRepligen Purchases Bioprocessing Analytics Portfolio from 908 DevicesBusiness WirePortfolio includes PAT devices for real-time process monitoring, control and analysis Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc.
- 1y agoRGENRepligen Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireFourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides
- 1y agoRGENRepligen to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireWALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company